Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces that the Extraordinary
nd generation novel bi-specific CAR-T therapy targeting both CD19 and CD20 antigens
Indications: Relapsed/refractory B-cell non-Hodgkin s lymphoma (B-NHL)
C-CAR039 has been developed as a novel 2nd generation 4-1BB bi-specific CAR-T targeting both CD19 and CD20 antigens with an optimized bi-specific antigen binding domain. C-CAR039 can eradicate CD19/CD20 single or double positive tumor cells
in vitro and
invivo. The tissue cross reactivity and whole genome membrane proteome array studies further confirmed the specificity of C-CAR039.
C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies. The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies. These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response. Clinical trial in
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
+7 (495) 641 33 77 Forward looking statement This announcement may contain forward-looking statements concerning Polyus and/or Polyus group. Generally, the words will , may , should , could , would , can , continue , opportunity , believes , expects , intends , anticipates , estimates or similar expressions identify forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Forward-looking statements include statements relating to future capital expenditures and business and management strategies and the expansion and growth of Polyus and/or Polyus group s operations. Many of these risks and uncertainties relate to factors that are beyond Polyus and/or Polyus group s ability to control or estimate precisely and therefore undue reliance should not be placed on such statements which speak only as at the date o
Celyad Oncology SA: Celyad Oncology Announces June 2021 Conference Schedule
Regulatory News:
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in June 2021:
Jefferies Virtual Healthcare Conference
Presentation date: Tuesday, June 1, 2021
Time: 11:00 a.m. EST 5:00 p.m. CET
Presenter: Filippo Petti, CEO
Events section of the Celyad Oncology website.
William Blair Company Annual Growth Stock Conference
Dates: Tuesday, June 1 Thursday, June 3, 2021
Presentation date: Wednesday, June 2, 2021